Augmented Package of Palliative Care for Women With Cervical Cancer: Responding to Refractory Suffering

Eric L. Krakauer, MD, PhD1,2,3; Khadidjatou Kane, MD1,4; Xiaoxiao Kwete, MD, MPH5; Gauhar Afshan, MBBS6; Lisa Bazzett-Matabele, MD7,8; Danta Donna Ruthnie Bien-Aimé, RN9,10,11; Lawrence F. Borges, MD12; Sarah Byrne-Martelli, DMin1; Stephen Connor, PhD13; Raimundo Correa, MD14; C. R. Beena Devi, MD15; Mamadou Diop, MD16; Shekinah N. Elmore, MD, MPH17; Nahla Gafer, MD18,19; Annekathryn Goodman, MD20,21; Surbhi Grover, MD22,23; Annette Hasenburg, MD24; Kelly Irwin, MD25; Mihir Kamdar, MD26; Suresh Kumar, MD27; Quynh Xuan Nguyen Truong, MPH28,29,30; Tom Randall, MD30,31; Maryam Rassouli, RN, PhD31; Cristiana Sessa, MD32; Dingle Spence, MBBS33,34; Ted Trimble, MD35; Cherian Varghese, MD, PhD36; and Elena Fidarova, MD36

INTRODUCTION

Cervical cancer, the fourth most common cancer in women globally and the most common cause of cancer-related death in sub-Saharan Africa,1 is associated with suffering that is more prevalent, complex, and severe than that associated with other malignancies.2,3 Elsewhere, we reported that women with cervical cancer have a higher prevalence of moderate or severe pain, anxiety, and depression than patients with cancer on average.2 They also suffer from a high prevalence of moderate or severe malodorous vaginal discharge, bleeding, sexual dysfunction, and financial distress, and more than 40% are abandoned by their intimate partners.2 In light of this extraordinarily prevalent, severe, and complex suffering, we convened a panel of experts in treatment and palliative care of women with cervical cancer to devise an essential package of palliative care for cervical cancer (EPPCCC).3

The EPPCCC, described elsewhere and summarized in Table 1, is designed to be the minimum package that can safely and effectively prevent and relieve most suffering associated with cervical cancer, to be applicable by any clinicians with basic palliative care training, and to be inexpensive enough to be made universally accessible free of charge to the patient even in the lowest-income settings.3 However, both available evidence and expert opinion suggest that cervical cancer frequently results in suffering too severe, complex, or refractory to be adequately relieved by basic palliative care.8-11 A variety of anatomic, physiologic, psychologically, and social factors appear to contribute to this phenomenon. For example, the proximity of major nerve plexuses to the cervix makes them susceptible to tumor invasion that often results in severe or refractory neuropathic pain.8,12 The large blood supply to the uterus and vagina puts patients with cervical cancer at risk of difficult-to-control hemorrhage,13-15 and disruption by necrotic tumor of the vaginal microbial environment often results in difficult-to-treat, psychosocially disabling vaginal discharge.15,16 The proximity of the cervix to bowel and bladder puts patients at risk for bowel obstruction with resultant intractable vomiting; rectovaginal, vesico- vaginal, and enterovesical fistulae with distressing leakage of stool and urine; and hydronephrosis with resultant renal failure. These distressing problems may...
be palliated best by surgical procedures.\textsuperscript{17} Severe psychosocial suffering that is difficult to relieve may result when invasive cervical cancer or its treatment injures the genitals and causes sexual dysfunction.\textsuperscript{18,19}

These data suggest that women with cervical cancer often experience suffering too severe, complex, or refractory to be controlled by basic palliative care. Thus, the group of experienced experts in cervical cancer treatment and palliation from countries of all income levels that created the EPPCCC agreed that an augmented package was necessary as a supplement to the EPPCCC. The augmented package includes the following:

1. Palliative radiotherapy
2. Advanced medical therapies
3. Nerve blocks for pain control
4. Palliative surgery
5. Psycho-oncology.

Governments should assure that the EPPCCC is universally accessible before approving even partial insurance coverage of expensive elements of the augmented package for which the poor may be unable to afford the co-payment. However, all governments should aspire to make accessible as much as possible of the augmented package as soon as possible. Implementation of each element of the augmented package requires advanced or specialist training in one or more of several disciplines: palliative care, radiation oncology, pain medicine, surgery, or psychiatry. Thus, the effort to make the augmented package accessible must entail efforts to create capacity for training in these disciplines wherever it is inadequate or nonexistent. Implementation of both packages will benefit not only women with cervical cancer but also patients with any serious illness.

**PALLIATIVE RADIATION THERAPY**

Patients with cervical cancer in low- and middle-income countries (LMICs) frequently present with locally advanced disease and associated symptoms.\textsuperscript{20,21} For these patients, palliative external beam radiation therapy (EBRT) often can provide rapid relief of vaginal bleeding or discharge and of pain because of the primary lesion, nodal disease, or metastatic disease in the mediastinum, neck, bone, or brain.\textsuperscript{22} Yet radiotherapy often is difficult or impossible to access in LMICs. Thus, making EBRT universally accessible with simple, reliable machines is crucial to fulfill the human right of patients with cancer to the highest attainable standard of health.\textsuperscript{23}

The most common palliative EBRT regimens for symptomatic pelvic cancers are shown in Table 2. They are ordered from most commonly used to least commonly used globally. Choice of regimen should be based on the patient’s prognosis, specific symptoms, performance status, ability to attend the radiotherapy center, and capacity of the treating center.\textsuperscript{22,26,32,33} Short regimens, such as 3.7 Gy twice daily for four fractions and up to three courses or 4-5 Gy daily for five fractions, are favored to balance effective symptom palliation with minimum logistical burden for patients, particularly when the prognosis may be limited. Conventional palliative regimens, such as 3 Gy for 10 fractions, are also safe and effective. However, they may be more burdensome for both patients and treatment centers and do not offer better symptom response. Single treatment regimens, such as 10 Gy for one fraction, offer convenience but have higher toxicity.

Ideally, radiotherapy clinics should be distributed widely enough to assure universal access and should be officially and operationally integrated with comprehensive palliative care services.\textsuperscript{34-36} Living accommodations should be made available for patients who must spend one or more nights at the radiotherapy facility. All radiation oncologists should have intermediate-level palliative care training, at least 60 hours per WHO recommendation, to promote this integration and to help assure an appreciation for the full spectrum of palliative interventions.\textsuperscript{37} Conversely, all levels
of palliative care training should include instruction on indications for radiotherapy. Available evidence indicates good economic return on investment in radiation therapy in LMICs, especially for cervical cancer. ADVANCED MEDICAL THERAPIES In addition to the medicines in the EPPCCC, several others can significantly improve comfort of women in specific clinical situations such as advanced-stage kidney disease or neuropathic pain refractory to all other medicines in the EPPCCC. Some of these medicines are more expensive than those in the EPPCCC, and others are not as well-studied, but they should be made accessible whenever possible for patients with these conditions. However, morphine in oral fast-acting and injectable preparations should be accessible to everyone in need before any more expensive opioid preparations are made available.

Lidocaine, Injectable
For moderate or severe pain that is refractory to opioids, or when opioids cause intolerable adverse effects, particularly near the end of life, an intravenous bolus (1-2 mg/kg over 30 minutes) can be given. If the bolus provides relief, a continuous infusion can be started (0.5-2 mg/kg/h) to maintain

| TABLE 1. Essential Package of Palliative Care for People Affected by Cervical Cancer |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Interventions** | **Medicines** | **Equipment** | **Social Supports** | **Human Resources** |
| 1. Prevention and relief of pain or other physical suffering | Amitriptyline, oral Bisacodyl (senna), oral Dexamethasone, oral and injectable Diazepam, oral and injectable Diphenhydramine (chlorpheniramine, cyclizine, or dimenhydrinate), oral and injectable Flucinazole, oral Fluoxetine (sertraline or citalopram), oral Furosemide, oral and injectable Haloperidol, oral and injectable Hyoscine butylbromide, oral and injectable Ibuprofen (naproxen, diclofenac, or meloxicam), oral Lactulose (sorbitol or polyethylene glycol), oral Loperamide, oral Metoclopramide, oral and injectable Metronidazole, oral (for both oral use and vaginal insertion) Morphine, oral immediate release and injectable Naloxone, injectable Omeprazole, oral Ondansetron, oral and injectable Oxygen Paracetamol, oral Iron and multivitamin supplement (oral) Petroleum jelly | Pressure-reducing mattresses Nasogastric drainage and feeding tubes. Urinary bladder catheterization kits. Roller gauze for vaginal packing Elastic compression bandages | Cash transfers or resource allocation for housing, children’s school tuition, transportation to health care facilities, or funeral costs. Other resource allocation (in-kind support): food packages, blankets, sleeping mats, shoes, soap, toothbrushes, and toothpaste | Doctors and clinical officers (with basic palliative care training) Nurse practitioners, midwives, or fieldshers (with basic palliative care training) Nurses (with basic palliative care training) Social workers, psychologists, grief counsellors, or trained and supervised lay counsellors CHWs (if available) Peer supporters Local spiritual counsellors (after vetting) |
| 2. Prevention and relief of psychological suffering | | | | |
| 3. Prevention and relief of social suffering | | | | |
| 4. Prevention and relief of spiritual suffering | | | | |

NOTE. Adapted. Abbreviations: CHW, community health worker; PTSD, post-traumatic stress disorder. On the basis of the WHO Model List of Essential Medicines 2019. Acceptable alternative medicines are in parentheses. At least for patients living in extreme poverty and for one caregiver per patient. Doctors may be oncologists, gynecologists, surgeons, general practitioners, family doctors, clinical officers or assistant doctors, or others. Other physical suffering includes breathlessness, weakness, nausea, vomiting, diarrhea, constipation, incontinence, malodorous vaginal discharge, and bleeding. Psychological suffering includes anxiety, depressed mood, PTSD, confusion or delirium, sexual dysfunction, and complicated grief. Only in hospitals that provide cancer chemotherapy or radiotherapy.
analgesia. The common side effects are usually mild or self-limited and dose-related and include perioral numbness, sedation, confusion, lightheadedness, and headache. Cardiac arrhythmia is a potential serious but low-risk adverse effect. Lidocaine can be combined with opioids as needed.

**Ketamine, Oral or Injectable**

For moderate or severe pain that is refractory to opioids, or when effective opioid doses cause intolerable adverse effects, ketamine can be added to enable reduction of opioid dose and improve analgesia. A typical starting dose is 2.5 mg orally or intravenously every 8 hours. If there is no benefit and also no adverse effect, the dose can be doubled on day 2 and again on day 3. The maximum dose is 0.5 mg/kg/dose. Contraindications include uncontrolled hypertension or high stroke risk. There is some evidence that ketamine can be used safely in patients with increased intracranial pressure and psychiatric illness.

**Slow-Release Oral Morphine**

For patients with moderate or severe cancer pain that is frequent or constant who can take oral medicines, slow-release oral morphine can reduce pill burden and provide more steady relief.

**Fentanyl Transdermal Patches**

This opioid preparation generally is better than morphine to treat moderate or severe cancer pain in noncachectic patients whose opioid requirement is stable and who are unable to take oral medicines or who have renal failure.

**Fentanyl, Injectable**

This is useful as a continuous infusion, with rescue bolus doses as needed, for moderate or severe pain that is frequent or constant in patients with renal failure or cachexia who are unable to take oral medicines. It is also useful for dose finding in noncachectic patients before applying fentanyl transdermal patch. Because of the rapid onset of action and short duration of action of injectable fentanyl, bolus doses alone are a good choice for preventing pain from brief procedures or dressing changes.

Injectable lidocaine, ketamine, and fentanyl are for use mainly in hospitals, but they can be provided in the home by palliative care specialist doctors if permitted by law and if clinically indicated.

Besides morphine and fentanyl, the other strong opioid on the WHO Model List of Essential Medicines for Pain and Palliative Care 2019 is methadone. Although methadone often can provide better relief for neuropathic pain than other opioids, we did not include it in the augmented package because opioid-refractory neuropathic pain can also be treated with other medicines in the essential and augmented packages, because of the relative complexity of its safe use, and so as not to risk complicating extremely important efforts in LMICs to use it to treat opioid use disorder.

**NEUROLYTIC PROCEDURES FOR RELIEF OF SEVERE OR REFRACTORY PAIN**

Pain impulses from the pelvic region are transmitted via somatic nerves from muscle, bone, skin, and connective tissue and via sympathetic and parasympathetic nerves and plexuses from visceral organs. Neurolytic procedures, and in some cases also neural stimulation, often can interrupt or modulate pain impulses transmitted within this neural network. However, because of the complexity of this pain network, adequate relief often requires multimodal treatment such as with both a neurolytic procedure and systemic pharmacotherapy.

**Nerve Blocks**

Neurolysis is the targeted destruction of a nerve or nerve plexus with chemical agents (alcohol or phenol), heat

---

**TABLE 2. Comparison of Palliative External Beam Radiation Therapy Regimens for Pelvic Cancers With Reported Rates of Symptom Control**

| Regimen | Repeated Treatments | Modality | Symptom Control Rates |
|---------|---------------------|----------|-----------------------|
| 3.7 Gy twice a day × 4 fx, once every 2-4 weeks × up to three courses | Yes, 59% compliance on trial | 2D or 3D | ORR 45% Bleeding 58%-75% Pain 98% |
| 4-5 Gy × 5 fx | No | 2D or 3D | Bleeding 94% Pain 67% |
| 4.5 Gy twice a day × 4 fx | No | 3D | ORR 89% Bleeding 100% Pain 93% |
| 3 Gy × 10 fx | No | 2D or 3D | Bleeding 88% Pain 65% |
| 10 Gy × 1 fx, monthly × up to 3 fx (10-by-3) | Yes, 47% compliance in LMICs | 2D or 3D | ORR 62% Bleeding 100% (third fx) Pain 41% (second fx) Vaginal discharge 29% (second fx) |

Abbreviations: fx, fraction (treatment); LMICs, low- and middle-income countries; ORR, overall response rate.

*Retrospective study.
(radiofrequency ablation), or cold (cryoablation). If the appropriate and adequately trained staff member(s) and necessary equipment are available, these procedures should be considered when pharmacologic pain treatment results in inadequate pain control or intolerable side effects. Typically, neurolytic blocks should be performed with fluoroscopic, ultrasonographic, or computed tomography guidance. Although these procedures are not effective for every patient, they usually provide some degree of analgesia, from partial to complete, that lasts from days to several months and reduces the opioid requirement.55-57

Neurolysis of the superior hypogastric plexus is the most common block for pelvic cancer pain. The superior hypogastric plexus lies anterior to the L5/S1 disk and innervates the cervix, uterus, bladder, and rectum. Complications such as neural injury, bowel perforation, retroperitoneal bleeding, bowel and bladder dysfunction, infection, and diarrhea are rare.50,55-57

Ganglion impar block is a safe and relatively easy procedure to treat visceral pelvic, perineal, and anal pain. The ganglion impar lies in the presacral space near the sacrococcygeal ligament and provides innervation to the perineum, distal rectum, distal urethra, vagina, and vulva. Image-guided neurolysis of the ganglion impar appears to be a generally safe and effective procedure.58-60

Intrathecal drug delivery systems infuse analgesics directly into the spinal fluid at the appropriate spinal level via a subcutaneous catheter connected to an implanted, refillable drug pump. This method of analgesia can be very effective but is expensive, requires specialized equipment and well-trained staff members, and should not be initiated during an infection.61-63 Because of the risk of permanent neurologic injury, intrathecal saddle neurolysis of the sacral nerve roots should be considered only as a last resort for severe refractory pain in a patient near the end of life.54-66

Neurosurgical Procedures

Where a skilled spine surgeon and the necessary support staff and facilities are available, transmission of pain impulses from pelvis to brain can also be interrupted by surgical intervention in the spine or brain.57 Chemical rhizotomy (severing of spinal nerve roots) by injecting alcohol into the lumbar subarachnoid space can be combined with percutaneous cordotomy,58 but skill and expertise are necessary to minimize risk of injury to other nerves. Another surgical option is to open the lumbar dura and cut the dorsal roots to the pelvis.59 For pelvic pain mainly on one side, the spinothalamic tract on the contralateral side of the spinal cord can be interrupted by an open surgical or percutaneous cordotomy. Cordotomy usually is performed only unilaterally because bilateral cordotomy has a high risk of permanent motor weakness.70-72

A visceral afferent nociceptive pathway is located between the dorsal columns of the spinal cord and can be interrupted by surgical laminectomy and midline myelotomy.73,74 This requires opening the spinal dura, usually at the T10 level, direct incision into the dorsal midline of the spinal cord between the dorsal columns over 1-2 cm in length, and extending within the spinal cord to the level of the central canal—about 5 mm deep. An operating surgical microscope is required to guide the incision and minimize damage to the dorsal columns, which are essential for balance and ambulation.75-78 There is some risk of meningitis with this procedure, and it should be performed only by well-trained and experienced neurosurgeons.

The neural pathways that interpret pain in the brain can also be interrupted by performing a stereotactic cingulotomy.79 This procedure requires access to a stereotactic frame and imaging to target the appropriate region of the brain. Good pain relief at three months has been reported in 64% of patients. Spinal cord stimulation, used primarily for non-cancer pain, can also be used for cancer pain. However, stimulators require surgical implantation and are expensive, and the wire leads tend to break.53,80

Palliative Surgical Procedures

Women with locally advanced or recurrent invasive cervical cancer may benefit from surgical procedures to palliate physical symptoms and emotional distress related to compromise of the urinary tract, intestinal tract, or vasculature. However, when deciding whether to intervene surgically, the potential benefits of the surgery must be weighed carefully against the risks and potential discomforts of the procedure itself in the context of the patient’s values and likely prognosis. Women who are medically fragile or are late in the course of their illness may be better served by non- or less-invasive interventions.

Ureteral obstruction often causes pain and acute kidney injury and can lead rapidly to destruction of function of one or both kidneys. If possible, this should be treated with placement of ureteral stents or, if necessary, percutaneous nephrostomy tubes. Fistulae of the distal urinary tract to the vagina or rectum may develop either because of direct instrumentation or as a complication of radiotherapy. Placement of flexible percutaneous nephrostomy tubes, ideally with simultaneous placement of coils in the ureters, can decrease or eliminate leakage of urine via a fistula from the vagina or rectum. However, provision must be made for urostomy bags.

The sigmoid colon or rectum can also become obstructed because of infiltration or compression by tumor, and fistulae can develop to the vagina or bladder. Colostomy can relieve large bowel obstruction and may decrease or eliminate fecal incontinence because of leakage via a fistula. It also may help prevent abscess formation or enable an existing abscess to heal after drainage and antibiotic treatment. In addition, some women may experience ulceration of the rectum as a complication of radiotherapy,
and colostomy may bring relief from any resulting pain, fecal frequency, or incontinence. Access to training in colostomy care and to an adequate supply of colostomy bags should be assured if colostomy is offered.

Local progression of cervical cancer may lead to catastrophic hemorrhage from compromise of major vessels or from tumor neovascularature. If the goal of care is not solely comfort but (also) to sustain life to some extent, emergent selective pelvic vessel embolization should be considered if experienced operators and adequate equipment are available.¹¹ If this is not an option, emergent palliative radiotherapy should be arranged, if possible. If neither embolization nor radiotherapy are available, tranexamic acid can be given, and the vagina can be tightly packed with simple roller gauge in a lithotomy position, with or without sedation or short general anesthesia depending on expected pain. A bladder catheter is needed while the pack is in place.⁸¹ If the only goal of care is comfort and the patient appears to be exsanguinating, pain, dyspnea, anxiety, or any other symptoms should be treated aggressively, even to the point of sedation if necessary to assure comfort.

Psycho-Oncology

Any doctor with basic palliative care training should be able to diagnose and treat uncomplicated anxiety or depressed mood with medicines in the EPPCCC, described elsewhere,³ and in LMICS, nurses, psychologists, social workers, and community health workers can be trained to provide simple, culturally appropriate supportive counseling and psychotherapy for uncomplicated depression.⁸²-⁸⁴ However, psychiatric or psycho-oncologic consultation is recommended for severe or refractory symptoms, for patients taking multiple psychoactive medicines, and for more complex psychiatric disorders such as bipolar disorder and psychotic disorders.⁸⁵,⁸⁶

Psycho-oncology, a subspecialty of psychiatry and psychology, addresses the psychological, social, behavioral, and cognitive problems related to cancer and cancer treatment. Psycho-oncologists collaborate with oncologists and palliative care providers to assess severe, complex, or refractory psychological and social suffering of patients with cancer and their family members and to plan and implement efforts to relieve this suffering.⁸⁷,⁸⁸ Specific competencies include diagnosis of psychological distress and comorbidities such as anxiety disorders, post-traumatic stress disorder, major depression, and sexual dysfunction; recognition of drug interactions and adverse psychological effects such as delirium; planning and implementing evidence-based psychopharmacologic and nonpharmacologic interventions; assistance with difficult discussions with patients or family members; and identification of optimum goals of care.⁹⁵-⁹⁷

Standard open-access measures used by psycho-oncologists to identify and diagnose psychosocial distress include the Distress Thermometer,⁸⁹ the Patient Health Questionnaire Anxiety and Depression Scale,⁹⁰ and the PROMIS emotional distress scales for cervical cancer.⁹¹ Treatment is tailored to the specific clinical situation. Evidence-based nonpharmacologic interventions for anxiety and depression include cognitive behavioral therapy, acceptance and commitment therapy, psychoeducation, and mindfulness and relaxation.⁸⁷,⁸⁸ Some patients benefit from existential interventions, such as dignity therapy, that promote meaning making, foster hope, and support expression of feelings at the end of life.⁹² Psycho-oncologists who are psychiatrists (medical doctors) can provide advice on the best pharmacologic interventions in a specific situation. Specialized psycho-oncologic consultation can be made accessible in LMICs via mobile phone or internet either as needed or as part of regular virtual tumor board conferences.

In conclusion, cervical cancer and its treatment sometimes result in suffering that is refractory to basic palliative care with the EPPCCC. Therefore, we propose an augmented package of palliative care for cervical cancer that can prevent or alleviate even refractory suffering. Some elements require special training or experience, and some medicines or equipment are expensive and will not be widely available in low-income settings. However, we propose that each element should be implemented as soon as possible by at least one referral center in a region, province, or state, in a manner that makes relief of refractory suffering accessible by all.

AFFILIATIONS

¹Division of Palliative Care & Geriatric Medicine, Massachusetts General Hospital, Boston, MA
²Departments of Medicine and of Global Health and Social Medicine, Harvard Medical School, Boston, MA
³Department of Palliative Care, University of Medicine & Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
⁴Department of Medicine, Harvard Medical School, Boston, MA
⁵Harvard School of Public Health, Boston, MA
⁶Department of Anaesthesiology, Aga Khan University Medical College, Karachi, Pakistan
⁷Department of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana
⁸Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT
⁹Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA
¹⁰Université Épiscopale d’Haiti, Port-au-Prince, Haiti
¹¹Faculté des Sciences Infirmières de Leogane, Leogane, Haiti
¹²Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA
¹³Worldwide Hospice Palliative Care Alliance, Fairfax, VA
¹⁴Gynecologic Oncology Unit & Palliative Care Service, Clinica Las Condes, Santiago, Chile
¹⁵Normah Medical Specialist Centre, Sarawak, Malaysia
¹⁶Cancer Institute of Cheikh Anta Diop University, Dakar, Senegal
CORRESPONDING AUTHOR
Eric L. Krakauer, MD, PhD, Division of Palliative Care & Geriatric Medicine, Massachusetts General Hospital, 55 Fruit Street/Founders 600, Boston, MA 02114; e-mail: ekrakauer@hms.harvard.edu.

DISCLAIMER
E.F., C.V. and E.L.K. are staff members or consultants of the WHO. The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the WHO.

SUPPORT
Funding for this study was provided by WHO and Unitaid.

AUTHOR CONTRIBUTIONS
Conception and design: Eric L. Krakauer, Khadijatou Kane, Xiaoxiao Kwete, Gauhar Afshan, Danta Dona Ruthnie Bien-Aimé, Lawrence F. Borges, Raimundo Correa, Cristiana Sessa, Cherian Varghese, Elena Fidarova
Collection and assembly of data: Eric L. Krakauer, Xiaoxiao Kwete, Nahla Gafer, Annekathryn Goodman, Kelly Irwin, Annette Hasenburg, Mihir Kamdar, Lawrence F. Borges, Shekinah N. Elmore, Quynh Xuan Nguyen Truong, Tom Randall, Cristiana Sessa, Dingle Spence, Ted Trimble, Elena Fidarova
Data analysis and interpretation: Eric L. Krakauer, Xiaoxiao Kwete, Lisa Bazzett-Matalebe, Sarah Byrne-Martelli, Stephen Connor, C. R. Bezerra Devi, Mamadou Diop, Shekinah N. Elmore, Nahla Gafer, Annekathryn Goodman, Surbhi Grover, Annette Hasenburg, Kelly Irwin, Mihir Kamdar, Quynh Xuan Nguyen Truong, Tom Randall, Cristiana Sessa, Dingle Spence, Ted Trimble, Elena Fidarova
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Eric L. Krakauer
Employment: (I) My wife is employed by Inform Diagnostics and Foundation Medicine

Xiaoxiao Kwete
Employment: Yaozhi Co Ltd
Stock and Other Ownership Interests: Expat Inc
Research Funding: Roche

Shekinah N. Elmore
Stock and Other Ownership Interests: Teladoc
Consulting or Advisory Role: Best Doctors Inc, Wildtype

Annette Hasenburg
Honoraria: AstraZeneca, Med Update, Pfizer, Roche, Streamedup!, Tesaro, MedConcept, LEO Pharma
Consulting or Advisory Role: PharmaMar, Tesaro, Roche, AstraZeneca, LEO Pharma, GliaxonSmithKline/MSD
Travel, Accommodations, Expenses: AstraZeneca, MedConcept, Roche, Streamedup!, Tesaro, MedUpdate, Pfizer

Mihir Kamdar
Leadership: Amorsa Therapeutics
Stock and Other Ownership Interests: Amorsa Therapeutics
Consulting or Advisory Role: Medtronic, Fern Health

Cristiana Sessa
Consulting or Advisory Role: Basilea

Ted Trimble
Consulting or Advisory Role: Merck, GliaxonSmithKline, Inovio Pharmaceuticals
Research Funding: Frantz Viral Therapeutics

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT
We are grateful to the following for helpful comments on drafts of the paper: Sally Agallo Kwenda, Esther Cege-Munyoro, Liliana de Lima, Lalaitul Ferdousi, Rei Haruyama, Kim Hulscher, Elizabeth Mattfeld, Diana Nezvorova, MR Rajagopal, Julie Torode, and Linda Van Le.
REFERENCES

1. Arbyn M, Weiderpass E, Brun L, et al: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health 8:e191-e203, 2020

2. Krakauer EL, Kwete X, Kane K, et al: Cervical Cancer-Associated Suffering: Estimating the Palliative Care Needs of a Highly Vulnerable Population. JCO Glob Oncol 7:62-72, 2021

3. Krakauer EL, Kane K, Kwete X, et al: An Essential Package of Palliative Care for Women with Cervical Cancer: Responding to the Suffering of a Highly Vulnerable Population. JCO Glob Oncol 7:873-885, 2021

4. World Health Organization (WHO): Integrating Palliative Care and Symptom Relief into Primary Health Care: A WHO Guide for Planners, Implementers and Managers. Geneva, World Health Organization, 2018. https://apps.who.int/iris/handle/10665/274559

5. Knaul FM, Farmer PE, Krakauer EL, et al: Alleviating the access abyss in palliative care and pain relief: An imperative of universal health coverage. Lancet 391:1391-1454, 2018

6. Krakauer EL, Kwete X, Verguet S, et al: Palliative care and pain control, in: Jamison DT, Gelband H, Horton S, et al (eds): Disease Control Priorities: Improving Health and Reducing Poverty, Volume 9 (ed 3). Washington, DC, World Bank, 2018, pp 235-246. https://openknowledge.worldbank.org/bitstream/handle/10986/28877/978164805271.pdf?sequence=2&isAllowed=y

7. World Health Organization (WHO): WHO Model List of Essential Medicines—21st List. Geneva, Switzerland, World Health Organization, 2019. https://www.who.int/publications/i/item/WHO-MVP-EPIAU2019.06

8. Palat G, Rajagopal MR: Pain management in cancer.oxov. Indian J Palliat Care 11:64-73, 2005

9. Pilkay J, Demiars C, Chochinov H, et al: Does gynecologic malignancy predict likelihood of a tertiary palliative care unit hospital admission? A comparison of local, provincial and national death rates. Palliat Support Care 10:249-254, 2012

10. Spoozak L, Sewo H, Liu Y, et al: Performance status and symptom scores of women with gynecologic cancer at the end of life. Int J Gynecol Cancer 23:971-978, 2013

11. Lefkowitz C, Rabow MW, Sherrman AE, et al: Predictors of high symptom burden in gynecologic oncology outpatients: Who should be referred to outpatient palliative care? Gynecol Oncol 132:698-702, 2014

12. Raymont C, Hermsdel MJ, Ass N, et al: Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative–Computerised symptom assessment study. Palliat Med 27:714-721, 2012

13. Fowler JM, Carpenter KM, Gupta P, et al: The Gynecologic oncology consult: Symptoms presentation and concurrent symptoms of depression and anxiety. Obstet Gynecol 103:1211-1217, 2004

14. Alméciga A, Rodriguez J, Beltrán J, et al: Emergency embolization of pelvic vessels in patients with locoregional advanced cervical cancer and massive vaginal bleeding: A case series in a Latin American oncologic center. JCO Glob Oncol 6:1376-1383, 2020

15. Allende-Perez S, Dominguez-Ocadir G, Velez-Salas V, et al: A snapshot of symptoms of advanced cervical cancer patients referred to the palliative care service in a cancer center in Mexico. Int J Gynaecol Obstet 153:335-339, 2020

16. Bates MJ, Mijoya A: A review of patients with advanced cervical cancer presenting to palliative care services at Queen Elizabeth Central Hospital in Blantyre, Malawi. Malaw Med J 27:99-105, 2015

17. Miner TJ: Palliative surgery for advanced cancer: Lessons learned in patient selection and outcome assessment. Am J Clin Oncol 28:411-414, 2005

18. Noor M, Mahomed SB, Schlebusch LS, Boss BA: Suicidal behavior in patients diagnosed with cancer of the cervix. Crisis 24:168-172, 2003

19. Maree JE, Holtslander L, Maree JE: The experiences of women living with cervical cancer in Africa: A metasynthesis of qualitative studies. Cancer Nurs, 2020.

20. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018

21. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015

22. van Lankhuijzen L, Thomas G: Palliative radiotherapy for cervical carcinoma, a systematic review. Radiat Oncol 98:287-291, 2011

23. Elmore SN, Grover S, Bourque JM, et al: Global palliative radiotherapy: A framework to improve access in resource-constrained settings. Ann Palliat Med 8:274-284, 2019

24. Spanos W, Guse C, Perez C, et al: Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: Preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys 17:659-661, 1989

25. Spanos W, Perez CA, Marcus S, et al: Effect of rest interval on tumor and normal tissue response—A report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol Phys 25:399-403, 1993

26. Kim DH, Lee JH, Yi KJ, et al: Short-course palliative radiotherapy for uterine cervical cancer. Radiat Oncol J 31:216-221, 2013

27. Caravatta L, Padula GD, Macchia A, et al: Short-course accelerated radiotherapy in palliative treatment of advanced cervical malignancies: a phase I study. Int J Radiat Oncol Biol Phys 83:e257-261, 2011

28. Farina E, Macchia G, Siepe G, et al: Palliative short-course radiotherapy in advanced pelvic cancer: A phase II study (SHARON project). Anticancer Res 39:4237-4242, 2019

29. E Choan, Quon M, Gallant V, et al: Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer. Gynecol Oncol 102:204-209, 2006

30. Mishra S, Bhatnagar S, Rana SP, et al: Efficacy of the anterior ultrasound-guided superior hypogastric plexus neurolysis in pelvic cancer pain in advanced gynecological cancer patients. Pain Med 14:837-842, 2013

31. Spanos WJ, Wasserman T, Meza R, et al: Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: Final report of RTOG phase I/II study. Int J Radiat Oncol Biol Phys 13:1479-1482, 1987

32. Krishnan MS, Racsa M, Yu H-HM: Handbook of Supportive and Palliative Radiation Oncology. Cambridge, MA, Academic Press, 2016

33. Mishra SK, Laskar S, Mukadame CA, et al: Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix. J Cancer Res Ther 1:208-212, 2005

34. Dennis K, Linden K, Balboni T, et al: Rapid access palliative radiation therapy programs: An efficient model of care. Future Oncol 11:2417-2426, 2015

35. Fairchild A, Pitskin E, Rose B, et al: The rapid access palliative radiotherapy program: Blueprint for initiation of a one-stop multidisciplinary bone metastases clinic. Support Care Cancer 17:163-170, 2009

36. Atun R, Jaffray D, Barto M, et al: Expanding global access to radiotherapy. Lancet Oncol 16:1153-1166, 2015

37. World Health Organization (WHO): Planning and Implementing Palliative Care Services: A Guide for Programme Managers. Geneva, Switzerland, World Health Organization, 2016. https://apps.who.int/iris/handle/10665/250584

38. Olson RA, Lengoc S, Tyldeley S, et al: Relationships between family physicians’ referral for palliative radiotherapy, knowledge of indications for radiotherapy, and prior training: A survey of rural and urban family physicians. Radiat Oncol 7:73, 2012
77. Filho OV, Araujo MR, Florencio RS, et al: CT-guided percutaneous punctate midline myelotomy for the treatment of intractable visceral pain: A technical note.

76. Becker R, Sure U, Bertalanffy H: Punctate midline myelotomy—a new approach in the management of visceral pain. Acta Neurochirurgica (Wien) 141:881-883, 2004

75. Hong D, Andren-Sandberg A: Punctate midline myelotomy: A minimally invasive procedure for the treatment of pain in inextensible abdominal and pelvic cancer.

74. Willis WD, Al-Chaer ED, Quast MJ, et al: A visceral pain pathway in the dorsal column of the spinal cord. Proc Natl Acad Sci USA 96:7675-7679, 1999

73. Hirshberg RM, Al-Chaer ED, Lawand NB, et al: Is there a pathway in the posterior funiculus that signals visceral pain? Pain 67:291-305, 1996

72. Hogberg T, Rebow L, Rosenberg P, et al: The use of chordotomy to treat pain from gynecologic cancer. Eur J Gynecol Obstet 173:41-44, 1991

70. Raslan AM, Ben-Haim S, Falowski SM, et al: Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by pelvic and/or perineal cancer pain. Neurosurgery 88:437-442, 2020

69. Son BC, Yoon JH, Kim DR, et al: Dorsal rhizotomy for pain from neoplastic lumbosacral plexopathy and advanced pelvic cancer. Stereotactic Funct Neurosurg 77:177-182, 2001

68. Ischia S, Luzzani A, Ischia A, et al: Subarachnoid neurectomy (L5-S1) and unilateral percutaneous cervical cordotomy in the treatment of pain secondary to pelvic malignant disease. Pain 20:139-149, 1984

67. Raslan AM, Ben-Haim S, Falowski SM, et al: The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. Neuro modulation 20:96-132, 2017 (Erratum: Neuro modulation 20:405-406, 2017)

66. Igarashi H, Sato S, Shiraishi Y: Saddle block using 10-20% tetracaine for patients with perineal pain due to recurrent rectal cancer. Anesthesiology 98:781-783, 2003

65. Ischia S, Luzzani A, Ischia A, et al: Subarachnoid neuraxial block for sacral cancer pain. Neurosurgery 20:4040-4049, 2002

64. Rodriguez-Bigas M, Petrelli NJ, Herrera L, et al: Intrathecal phenol rhizotomy for management of pain in recurrent unsectable carcinoma of the rectum. Surg Gynecol Obstet 173:41-44, 1991

63. Deer TR, Pope JE, Hayek SM, et al: The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. Neuro modulation 20:96-132, 2017 (Erratum: Neuro modulation 20:405-406, 2017)

62. Deer TR, Smith HS, Burton AW, et al: Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician 14:E283-E312, 2011

61. Smith TJ, Staats PS, Deer T, et al: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040-4049, 2002

60. Sousa Correia J, Silva M, Castro C, et al: The efficacy of the ganglion impar block in perineal and pelvic cancer pain. Support Care Cancer 27:4327-4330, 2019

59. Smith TJ, Staats PS, Deer T, et al: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040-4049, 2002

58. Plancarte R, Amescua C, Patt RB, et al: Presacral blockade of the ganglion of Walther (ganglion impar). Anesthesiology 73:A751, 1990

57. Son BC, Yoon JH, Kim DR, et al: Dorsal rhizotomy for pain from neoplastic lumbosacral plexopathy and advanced pelvic cancer. Stereotactic Funct Neurosurg 77:177-182, 2001

56. Rigor BM: Pelvic cancer pain. J Surg Oncol 114:155-170, 2011

55. Hunter CW, Stovall B, Chen G, et al: Anatomy, pathophysiology and interventional therapies for chronic pelvic pain: A review. Pain Physician 21:147-167, 2018

54. Eid S, Iwanga J, Chapman J, et al: Superior hypogastric plexus and its surgical implications during spine surgery. A review. World Neurosurg 120:163-167, 2018

53. Hunter CW, Stovall B, Chen G, et al: Anatomy, pathophysiology and interventional therapies for chronic pelvic pain: A review. Pain Physician 21:147-167, 2018

52. Rigor BM: Pelvic cancer pain. J Surg Oncol 114:155-170, 2011

51. Son BC, Yoon JH, Kim DR, et al: Dorsal rhizotomy for pain from neoplastic lumbosacral plexopathy and advanced pelvic cancer. Stereotactic Funct Neurosurg 77:177-182, 2001

50. Prommer EE: Ketamine for pain: An update of uses in palliative care. J Palliat Med 15:474-483, 2012

49. Watanabe Nemoto M, Natsuko Nozaki-Taguchi N, Togasaki G, et al: New approach to relieving pain and distress during high-dose-rate intracavitary irradiation for cervical cancer. Brachytherapy 14:642-647, 2015

48. Bredlau AL, Thakur R, Korones DN, et al: Ketamine for pain in adults and children with cancer: A systematic review and synthesis of the literature. Pain Med 14:1505-1517, 2013

47. Prommer EE: Ketamine for pain: An update of uses in palliative care. J Palliat Med 15:474-483, 2012

46. Bell RF, Kalso E: Subanesthetic Ketamine for Cancer Pain and Scientific Rigor in Cancer Pain Trials. A Reply to Jackson et al. J Pain Symptom Manage 31:386, 2006

45. Jackson K, Ashby M, Goodchild C: Subanesthetic ketamine for cancer pain: By insisting on level III evidence, do we risk throwing the baby out with the bath water? J Pain Symptom Manage 29:328-330, 2005

44. Kotli ´nska-Lemieszek A, Jacek Luczak J: Subanesthetic ketamine: An essential adjuvant for intractable cancer pain. J Pain Symptom Manage 20:100-102, 2004

43. Raslan AM, Ben-Haim S, Falowski SM, et al: Congress of Neurological Surgeons systematic review and evidence-based guideline on neuroablative procedures for patients with cancer pain. Neurosurgery 88:437-442, 2020

42. Thomas J, Kronenberg R, Cox MC, et al: Intravenous lidocaine relieves severe pain: Results of an inpatient hospice chart review. J Palliat Med 7:660-667, 2004

41. Sharma S, Rajagopal MR, Gayatri Palat G, et al: A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 37:85-93, 2009

40. Pallium India, International Association for Hospice and Palliative Care, and the Pain & Policy Studies Group: A morphine manifesto. J Pain Palliat Care Pharmacother 26:144-145, 2012

39. Rodin D, Burger EA, Atun R, et al: Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: A model-based analysis of need and economic impact. Lancet Oncol 20:915-923, 2019

38. Thomas J, Kronenberg R, Cox MC, et al: Intravenous lidocaine relieves severe pain: Results of an inpatient hospice chart review. J Palliat Med 7:660-667, 2004

37. Jackson K, Ashby M, Goodchild C: Subanesthetic ketamine for cancer pain: By insisting on level III evidence, do we risk throwing the baby out with the bath water? J Pain Symptom Manage 29:328-330, 2005
80. Flagg A, McGreevy K, Williams K: Spinal cord stimulation in the treatment of cancer-related pain: “Back to the origins”. Curr Pain Headache Rep 16:343-349, 2012
81. Mishra K: Gynaecological malignancies from palliative care perspective. Indian J Palliat Care 17:S45-S51, 2011 (suppl)
82. Belkin GS, Unutzer J, Kessler RC, et al: Scaling up for the “bottom billion”: “5x5” implementation of community mental health care in low-income regions. Psychiatr Serv 62:1494-1502, 2011
83. Patel V: Where There Is No Psychiatrist: A Mental Health Care Manual. London, United Kingdom, Gaskell, 2003
84. Weobong B, Weiss HA, McDaid D, et al: Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial. PLoS Med 14:e1002385, 2017
85. Huffman LB, Hartenbach EM, Carter J, et al: Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide. Gynecol Oncol 140:359-368, 2016
86. Riba MB, Donovan KA, Andersen B, et al: Distress management, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:1229-1249, 2019
87. Andersen BL, DeRubeis RJ, Berman BS, et al: Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: An American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605-1619, 2014
88. Weis J, Hasenburg A: Psychological support, in: Ayhan ARN, Gultekin M, Dursun P (eds): Textbook of Gynaecological Oncology (ed 3). Ankara, Turkey: Gunes Publishing, 2016, pp 1495-1499
89. Donovan KA, Grassi L, McGinty HL, et al: Validation of the distress thermometer worldwide: State of the science. Psychooncology 23:241-250, 2014
90. Kroenke K, Wu J, Yu Z, et al: The Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS): Initial validation in three clinical trials. Psychosom Med 78:716-727, 2016
91. Wilford J, Osann K, Hsieh S, et al: Validation of PROMIS emotional distress short form scales for cervical cancer. Gynecol Oncol 151:111-116, 2018
92. Li M, Kennedy EB, Byrne N, et al: Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology 26:573-587, 2017
93. Bauereiß N, Obermaier S, Özunal SE, et al: Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: Systematic review and meta-analysis of randomized controlled trials. Psychooncology 27:2631-2645, 2018